News

A recent National Institutes of Health (NIH) study shows that moderate to vigorous exercise can help reduce hypertension in African-Americans. The observational study, “Physical Activity and Incident Hypertension in African Americans,” was conducted with participants enrolled in the Jackson Heart Study, a large, community-based analysis of cardiovascular disease in…

Researchers have shown that assessing vasculature structures by magnetic resonance imaging (MRI) can retrieve important information and has predictive potential for pulmonary arterial hypertension (PAH) patients. In combination with clinical data, MRI can increase the accuracy of determining PAH severity and outcomes, and improve decisions regarding therapies. The finding, from researchers…

Adcirca (tadalafil) improved the pulmonary arterial hypertension (PAH) of 29 percent of patients in a real-world study in Japan, researchers said. They two-year study also found the treatment to be safe, with acceptable rates of side effects. A real-world study covers a patient group with a wider range of characteristics than…

The patch that delivers SteadyMed’s pulmonary arterial hypertension (PAH) treatment Trevyent (treprostinil) to patients is effective, safe and tolerable, according to a company study. Treprostinil is a vasodilatory prostacyclin analogue, or synthetic version of prostacyclin, a substance that helps prevent arteries from constricting and blood platelets from clumping together. Prostacyclin is deficient in…

Massachusetts, which adopted the nation’s first pulmonary hypertension (PH) law in January, has named the first members of an expert task force dealing with PH patient care. The PH law, signed by Massachusetts Gov. Charlie Baker, requires the state to establish the task force to monitor and report on research, transplants, public awareness,…

The Pulmonary Hypertension Association (PHA) is joining Periwinkle Hearts Around the World, an 80-organization international campaign to raise awareness of pulmonary hypertension (PH) patients’ need for better access to care. Stiffness in the lung’s arteries and veins causes the high lung blood pressure that characterizes PH. Patients experience shortness of…

A Japanese study of nine families members who have heritable pulmonary arterial hypertension (HPAH) found different mutations in the same gene, called BMPR2, four of which had been identified before and four newly identified. Researchers also found a new mutation in another gene, KCNK3, that caused HPAH in another family. The researchers believe…

Two U.S. companies, Respira Therapeutics and United Therapeutics, will jointly develop and license RT234 and its dry-powder inhaler drug delivery technology AOS-DPI to treat pulmonary hypertension (PH) in the United States. Under the agreement, United, based in Silver Spring, Md., will finance the development of RT234 towards its approval by the U.S. Food and Drug…

A simple test with cord blood could predict which babies are at risk of developing a severe lung disease called bronchopulmonary dysplasia-associated pulmonary hypertension (BPD-PH), according to a study. If scientists can validate the test’s predictive ability, doctors could intervene to try to prevent the disease immediately after a baby is…

Pulmonary arterial hypertension (PAH) patients have given high marks to a new implanted,  programmable intravenous (IV) system that delivered Remodulin (treprostinil) to them with few complications, according to a clinical trial. The study, “Treprostinil Administered to Treat Pulmonary Arterial Hypertension Using a Fully Implantable Programmable Intravascular Delivery System…

The INOpulse inhaled nitric oxide (iNO) delivery system improved lung-pressure measurements in pulmonary arterial hypertension (PAH) patients, according to its maker, Bellerophon Therapeutics. It presented the results at the 37th Annual Meeting of the International Society for Heart and Lung Transplantation (ISHLT) in San Diego April 5-8. The title of…

The European Medicines Agency (EMA) has completed its review of Uptravi (selexipag) and concluded that doctors may continue prescribing the drug to treat pulmonary arterial hypertension (PAH), according to a press release. The 28-member European Union approved Uptravi for treating PAH in May 2016. However, after…